| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | Herbert Kevin R. EVP & President, North America | Sale | -2,000 | -3.93%48,866 | $20.68 | $41,364 | View SEC filing | |
| 2026-06-11 | Yates Bryant J EVP & President, Europe | Sale | -11,968 | -13.38%77,446 | $19.90 | $238,163 | View SEC filing | |
| 2026-06-03 | Norman Daniel C EVP & President, Asia | Sale | -9,713 | -17.04%47,276 | $20.64 | $200,476 | View SEC filing | |
| 2026-05-22 | Brower Nathan G EVP, General Counsel | Sale | -12,015 | -21.67%43,438 | $21.84 | $262,408 | View SEC filing | |
| 2026-03-17 | Yates Bryant J EVP & President, Europe | Sale | -19,516 | -18.65%85,154 | $24.35 | $475,215 | View SEC filing | |
| 2026-03-17 | Norman Daniel C EVP & President, Asia | Sale | -15,383 | -21.64%55,693 | $24.52 | $377,191 | View SEC filing | |
| 2026-03-16 | Lanoy Jonathan David SVP, Chief Accounting Officer | Sale | -4,000 | -7.94%46,405 | $24.70 | $98,800 | View SEC filing | |
| 2025-12-16 | Yates Bryant J EVP & President, Europe | Sale | -1,700 | -1.69%98,604 | $22.29 | $37,893 | View SEC filing | |
| 2025-11-19 | Norman Daniel C EVP & President, Asia | Sale | -8,884 | -11.76%66,636 | $20.46 | $181,767 | View SEC filing | |
| 2025-11-19 | Lanoy Jonathan David SVP, Chief Accounting Officer | Sale | -5,000 | -9.76%46,233 | $20.45 | $102,250 | View SEC filing | |
| 2025-11-18 | Brower Nathan G EVP, General Counsel | Sale | -3,800 | -7.52%46,735 | $20.81 | $79,078 | View SEC filing | |
| 2025-09-04 | Yates Bryant J EVP & President, Europe | Sale | -9,672 | -9.02%97,498 | $16.74 | $161,919 | View SEC filing | |
| 2025-08-15 | Lanoy Jonathan David SVP, Chief Accounting Officer | Sale | -5,000 | -9.08%50,051 | $16.51 | $82,550 | View SEC filing | |
| 2025-08-15 | Brower Nathan G EVP, General Counsel | Sale | -9,996 | -17.15%48,277 | $16.54 | $165,334 | View SEC filing | |
| 2025-06-27 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10% Owner | Sale | -2,854,607 | -100.00%0 | $11.46 | $32,713,796 | View SEC filing | |
| 2024-10-17 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10% Owner | Sale | -2,300 | -3.46%64,167 | $13.02 | $29,946 | View SEC filing | |
| 2024-10-15 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. 10% Owner | Sale | -10,895 | -14.08%66,467 | $13.33 | $145,189 | View SEC filing | |
| 2024-06-24 | Yates Bryant J EVP & President, Europe | Sale | -3,068 | -3.01%98,852 | $15.30 | $46,940 | View SEC filing | |
| 2023-12-01 | Norman Daniel C EVP & President, Asia | Sale | -15,000 | -21.50%54,765 | $17.13 | $256,960 | View SEC filing | |
| 2023-11-27 | Brower Nathan G EVP, General Counsel | Sale | -3,999 | -8.37%43,760 | $17.31 | $69,223 | View SEC filing | |
| 2023-08-31 | Yates Bryant J EVP & President, Europe | Sale | -15,000 | -13.74%94,150 | $16.77 | $251,550 | View SEC filing | |
| 2023-08-29 | Norman Daniel C EVP & President, Asia | Sale | -12,236 | -0.29%69,765 | $16.40 | $200,690 | View SEC filing | |
| 2023-06-21 | Yates Bryant J EVP & President, Europe | Sale | -9,468 | -9.00%95,703 | $11.63 | $110,083 | View SEC filing | |
| 2023-06-21 | Norman Daniel C EVP & President, Asia | Sale | -15,470 | -17.03%75,366 | $11.18 | $172,914 | View SEC filing | |
| 2023-06-01 | Brower Nathan G EVP, General Counsel | Sale | -11,396 | -18.85%49,053 | $10.97 | $124,969 | View SEC filing |
1-25 of 262
